A Biomarker-Directed, Multi-Centre Phase II/III Study of ctDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer - BR.36

Status

Not yet recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-522084-15-00

Enrollment

Registered

2026-01-13

Start date

Unknown

Completion date

Unknown

Last updated

2026-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

metastatic NSCLC patients

Brief summary

progression free survival (PFS) - Overall survival (OS)

Detailed description

Feasibility

Interventions

DRUGAbraxane 5 mg/ml powder for dispersion for infusion.

DRUGCISPLATIN

DRUGPEMBROLIZUMAB

DRUGCARBOPLATIN

DRUGPACLITAXEL

DRUGPEMETREXED

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
progression free survival (PFS) - Overall survival (OS)	—

Secondary

Measure	Time frame
Feasibility	—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026